Lucerna Inc.

Lucerna Inc. is a minority-owned and woman-owned small business corporate entity registered in SAM.gov since 2010, focusing on advanced biomedical research and development of innovative technological platforms for drug discovery. The company specializes in developing cutting-edge RNA-based technologies and diagnostic tools that enable more efficient screening and evaluation of potential therapeutic interventions across various disease domains. With a strong emphasis on proprietary fluorogenic RNA aptamer technology, Lucerna Inc. appears to leverage advanced molecular engineering techniques to create novel in vivo imaging and screening platforms that can transform preclinical research methodologies.

The company has secured multiple federal grants from prestigious national institutes, including the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Allergy and Infectious Diseases, and National Institute on Aging. Lucerna's grant-funded projects concentrate on developing high-throughput screening assays and innovative diagnostic technologies for challenging medical conditions such as myotonic dystrophy type 1 (DM1), viral diseases like dengue and influenza, neurodegenerative disorders including amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and synucleinopathies. Their research primarily focuses on creating advanced cell-based RNA degradation assays, targeted RNA detection platforms, and non-invasive imaging technologies that can monitor RNA dynamics, toxic protein aggregation, and potential drug interactions at the molecular level. These projects aim to overcome current limitations in drug discovery by providing more efficient, precise, and adaptable screening methodologies that could potentially accelerate therapeutic development across multiple complex disease domains.